{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:33:53Z","timestamp":1790771633499,"version":"4.1.0"},"reference-count":42,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15264","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:34:40Z","timestamp":1757421280000},"page":"1-11","source":"Crossref","is-referenced-by-count":2,"title":["Meta\u2011analysis of the efficacy and safety of thoracic radiotherapy for extensive\u2011stage small cell lung cancer\u00a0 in the era of immunotherapy"],"prefix":"10.3892","volume":"30","author":[{"given":"Meiqiao","family":"Jiang","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu 730030, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Gansu Provincial Cancer Hospital, Lanzhou, Gansu 730050, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhaoyun","family":"Long","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu 730030, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinning","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu 730030, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu 730030, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"key20251007110330_b1-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","article-title":"Evolutionary trajectories of small cell lung cancer under therapy","volume":"627","author":"George","year":"2024","journal-title":"Nature"},{"key":"key20251007110330_b2-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cllc.2016.05.008","article-title":"No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: A literature-based meta-analysis of randomized trials","volume":"17","author":"Roviello","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"key20251007110330_b3-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"key20251007110330_b4-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20251007110330_b5-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide vs. platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20251007110330_b6-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide vs. platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"key20251007110330_b7-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs. placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"key20251007110330_b8-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4143\/crt.2023.931","article-title":"Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy","volume":"56","author":"Kim","year":"2024","journal-title":"Cancer Res Treat"},{"key":"key20251007110330_b9-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.1999.17.7.2092","article-title":"Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study","volume":"17","author":"Jeremic","year":"1999","journal-title":"J Clin Oncol"},{"key":"key20251007110330_b10-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","article-title":"Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG oncology RTOG 0937","volume":"12","author":"Gore","year":"2017","journal-title":"J Thorac Oncol"},{"key":"key20251007110330_b11-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: A phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"key20251007110330_b12-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: Comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"key20251007110330_b13-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"key20251007110330_b14-ol-30-5-15264","article-title":"Updating a review [last updated August 2023]","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Cumpston","year":"2024"},{"key":"key20251007110330_b15-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"e842","DOI":"10.1097\/CAD.0000000000001374","article-title":"Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy","volume":"33","author":"Wu","year":"2022","journal-title":"Anticancer Drugs"},{"key":"key20251007110330_b16-ol-30-5-15264","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer J Clin"},{"key":"key20251007110330_b17-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"key20251007110330_b18-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.neo.2017.07.007","article-title":"What's new in SCLC? A review","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"key20251007110330_b19-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.semcancer.2022.02.021","article-title":"Evolving role of immunotherapy in small cell lung cancer","volume":"86","author":"Barrows","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"key20251007110330_b20-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"1132482","DOI":"10.3389\/fimmu.2023.1132482","article-title":"Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"key20251007110330_b21-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"e1822","DOI":"10.1002\/onco.13900","article-title":"Radiation versus immune checkpoint inhibitor associated pneumonitis: Distinct radiologic morphologies","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"key20251007110330_b22-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"100883","DOI":"10.1016\/j.adro.2021.100883","article-title":"Consolidative thoracic radiation therapy after first-line chemotherapy and immunotherapy in extensive-stage small cell lung cancer: A multi-institutional case series","volume":"7","author":"Diamond","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"key20251007110330_b23-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10585-023-10227-5","article-title":"Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world","volume":"40","author":"Fang","year":"2023","journal-title":"Clin Exp Metastasis"},{"key":"key20251007110330_b24-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12672-023-00666-7","article-title":"Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemo-immunotherapy: A retrospective study from a single cancer center","volume":"14","author":"Li","year":"2023","journal-title":"Discov Oncol"},{"key":"key20251007110330_b25-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41591-020-01190-9","article-title":"Liver metastases inhibit immunotherapy efficacy","volume":"27","author":"Lindblad","year":"2021","journal-title":"Nat Med"},{"key":"key20251007110330_b26-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41568-021-00338-0","article-title":"Liver metastases cultivate an immune desert","volume":"21","author":"O'leary","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"key20251007110330_b27-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10555-024-10220-8","article-title":"Small cell lung cancer with liver metastases: From underlying mechanisms to treatment strategies","volume":"44","author":"Fan","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"key20251007110330_b28-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N Engl J Med"},{"key":"key20251007110330_b29-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ijrobp.2020.09.031","article-title":"Prospective single-arm phase 1 and 2 study: ipilimumab and nivolumab with thoracic radiation therapy after platinum chemotherapy in extensive-stage small cell lung cancer","volume":"109","author":"Perez","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20251007110330_b30-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"1289434","DOI":"10.3389\/fimmu.2023.1289434","article-title":"Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemo-immunotherapy: Preclinical data and a retrospective study in Southern Italy","volume":"14","author":"Longo","year":"2024","journal-title":"Front Immunol"},{"key":"key20251007110330_b31-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13014-024-02420-x","article-title":"Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: A propensity score matched multicentre retrospective analysis","volume":"19","author":"Yao","year":"2024","journal-title":"Radiat Oncol"},{"key":"key20251007110330_b32-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12885-023-10784-8","article-title":"First-line atezolizumab\/durvalumab plus platinum\u2013etoposide combined with radiotherapy in extensive-stage small-cell lung cancer","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"key":"key20251007110330_b33-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00066-023-02075-9","article-title":"Is consolidative thoracic radiotherapy of extensive-stage small cell lung cancer still beneficial in the era of immunotherapy? A retrospective analysis","volume":"199","author":"Hoffmann","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"key20251007110330_b34-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jtho.2019.10.001","article-title":"Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer","volume":"15","author":"Welsh","year":"2020","journal-title":"J Thorac Oncol"},{"key":"key20251007110330_b35-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.3390\/jcm12113828","article-title":"Real-world efficacy and safety of thoracic radiotherapy after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer","volume":"12","author":"Xie","year":"2023","journal-title":"J Clin Med"},{"key":"key20251007110330_b36-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13014-023-02308-2","article-title":"Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer","volume":"18","author":"Peng","year":"2023","journal-title":"Radiat Oncol"},{"key":"key20251007110330_b37-ol-30-5-15264","first-page":"236","article-title":"Safety of thoracic radiotherapy followed by PD-1\/PD-L1 inhibitors after induction therapy in extensive-stage small cell lung cancer","volume":"31","author":"Liu","year":"2022","journal-title":"Chin J Radiat Oncol"},{"key":"key20251007110330_b38-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"8563","DOI":"10.1200\/JCO.2022.40.16_suppl.8563","article-title":"Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20251007110330_b39-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1016\/j.ijrobp.2021.07.1303","article-title":"Role of thoracic radiotherapy in extensive stage small cell lung cancer (ES-SCLC) in the immunotherapy era: A national hospital-based registry analysis","volume":"111","author":"Gross","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20251007110330_b40-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/j.annonc.2022.02.175","article-title":"144P Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO)","volume":"33","author":"Daher","year":"2022","journal-title":"Ann Oncol"},{"key":"key20251007110330_b41-ol-30-5-15264","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.21037\/tlcr-23-294","article-title":"Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: A multicenter retrospective analysis","volume":"12","author":"Cai","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"key20251007110330_b42-ol-30-5-15264","first-page":"110","article-title":"Clinical study of first-line chemotherapy and immunotherapy combined with thoracic radiotherapy for extensive-stage small cell lung cancer","volume":"33","author":"Meng","year":"2024","journal-title":"Chin J Radiat Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:04:22Z","timestamp":1759824262000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15264","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}